Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of hepatitis-C-focused biotechnology firm Idenix Pharmaceuticals
So what: Idenix Pharmaceuticals received word from the Food and Drug Administration in a letter today that it was placing a hold on IDX184, a mid-stage treatment for hepatitis C that had shown significant efficacy in recent studies. According to the FDA, the reason for the hold stems from an adverse cardiac event that happened with a competitors' nucleotide polymerase inhibitor. That letter is referring to Bristol-Myers Squibb
Now what: Don't for one second think this is a reason to run out and buy Achillion Pharmaceuticals
Craving more input? Start by adding Idenix Pharmaceuticals to your free and personalized watchlist so you can keep up on the latest news with the company.
Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.
Motley Fool newsletter services have recommended buying shares of Vertex Pharmaceuticals and Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Biotech M&A: Do We Need a New Driver?
Hepatitis C acquisitions like we've seen from Gilead, Bristol-Myers Squibb, and Merck can't last forever.
3 Stocks That Soared Stupendously This Week
2 of this week's biggest health-care winners scored triple-digit gains with another jumping over 40%. Here's how they did it.
This Week in Biotech: Tulipmania Ensues in the Hepatitis C Sector
Five clinical updates that made waves in the biotech sector this week, as well as the surprising buyout that still has Wall Street abuzz.